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Background/aim: Fanconi anemia (FA) is an autosomal recessive disease determined by mutations in at least 16 genes, with distinct
distributions in different populations. To the best of our knowledge, there are no reports regarding the molecular basis of the disease in
FA patients in Pakistan. The current study aimed to determine the frequency of FANCC gene mutations, i.e. IVS4+4A>T, del322G, and
R548X, in FA patients.
Materials and methods: Genomic DNA was obtained from 36 FA patients. All samples were analyzed by polymerase chain reaction and
restriction fragment length polymorphism techniques.
Results: Mutation IVS4+4A>T was identified in 26 (72.2%) patients. It was homozygous in 6 and heterozygous in 20 patients. Del322G
and R548X were found with the following prevalences: del322G, 5.6%, and R548X, 5.6%. Patients with these two mutations were
compound heterozygotes having concomitant IVS4+4A>T mutation.
Conclusion: These results suggest that mutation IVS4+4A>T is the most prevalent mutation in our group of patients. This analysis of
Pakistani patients also suggests that there is no significant difference between IVS4+4A>T homozygotes and the rest of the patients with
regard to severity of clinical phenotype.
Key words: Fanconi anemia, IVS4+4A>T, Del322G, R548X, FANCC

1. Introduction
Fanconi anemia (FA) is a rare autosomal recessive or
X-linked genomic instability disorder characterized
by hypersensitivity to DNA cross-linking reagents,
chromosomal breakage, progressive bone marrow failure,
pancytopenia, developmental delay, diverse congenital
abnormalities, and a predisposition to solid tumors and
leukemias (1). It is the most common type of inherited
bone marrow failure syndrome (2). The genetic basis of
FA is heterogeneous and many genes are involved in its
pathogenesis. Mutations in these genes that code for their
respective proteins have been identified in patients with
FA (3). The birth incidence of FA is around three per one
million. The disease is slightly more common in males than
* Correspondence: iram-aftab@hotmail.com

females; the ratio is 1.3:1 due to the FANCB gene, which is
located on the X chromosome. The estimated heterozygote
frequency is one in 300 in Europe and the United States.
Its frequency is higher in Afrikaners, Spanish Romani,
and Ashkenazi Jews at one in 100. FA is present in all
ethnic groups (4). Between 1927 and 2001, 1300 cases of
FA were reported in the literature with varying clinical
presentations (5).
It is now known that mutations in at least 16 distinct
genes with a total of 307 exons are responsible for FA onset,
i.e. FANCA, FANCB, FANCC, FANCD1/BRCA2, FANCD2,
FANCE, FANCF, FANCG, FANCI, FANCJ/BRIP1, FANCL,
FANCM, FANCN/PALB2, FANCO/RAD51C, FANCP/
SLX4, and FANCQ/ERCC4. The products of these 16 genes
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are thought to function in a common DNA repair pathway,
the FA pathway. These proteins, along with other DNA
repair proteins, remove interstrand crosslinks (6). All the
genes are quite different from each other and show little or
no homology. With the exception of FANCC and FANCG,
which are both located on chromosome 9, and FANCA
and FANCN, which are both located on chromosome 16,
the other FA genes are spread over different chromosomes
(7). Most FA patients belong to complementation group A,
C, or G and their approximate percentage according to the
International Fanconi Anemia Registry (IFAR) is as follows:
FA-A = 65%, FA-C = 15%, and FA-G = 10%. However,
group C is most frequent in Ashkenazi Jews. Its mutations
lead to absent or reduced protein production that results
in a build-up of DNA errors. Affected individuals develop
congenital abnormalities and pancytopenia (8).
Mutation IVS4+4A>T is a splice site mutation and
results in deletion of the entire exon 4. Cells with this
mutation express a truncated protein of 55 kDa. The
truncated protein is functionally inactive (9). The exon 1
mutation, del322G, is a frame-shift mutation and results
in a premature stop codon. It involves deletion of a single
G at base 322 and consequently a truncated protein of
44 amino acids is produced (10). Similarly, a truncated
protein is also produced when thymine is inserted at 1897
bp instead of cytosine in exon 14. This shorter protein is
nonfunctional and results from premature termination of
protein synthesis, due to mutation R548X in exon 14 (11).
Therefore, this study was designed to determine the
frequency of FANCC gene mutations, i.e. IVS4+4A>T,
del322G, and R548X, in patients with FA in Pakistan.
2. Materials and methods
2.1. Patients
All unrelated patients with confirmed FA who attended
the medical, genetic, and hematological services of the
Combined Military Hospital and Armed Forces Institute of
Pathology were recruited for the present study. Peripheral
blood samples were collected from 50 individuals after
their informed consent was obtained. Diagnosis of the
disease was based on clinical and laboratory data, including
hematological analysis, bone marrow aspiration, and
biopsy, and was confirmed by DEB test. The study protocol
was approved by the institutional ethics committee.
2.2. DEB/MMC test
The DEB test was performed according to conventional
methods (12). It was performed on 50 patients and 36 of
these turned out to be DEB-positive. They were included
in the study. The DEB/MMC test was done on peripheral
blood lymphocytes stimulated with phytohemagglutinin
in 72-h cultures. Cultures were paired with a replicate
set of cultures to serve as untreated controls. MMC at a
final concentration of 0.1 µg/mL was also added to the
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treated cultures. In addition, negative controls from
phenotypically normal subjects were also set up for each
patient. Analysis was performed on 50 Giemsa-stained
metaphases. Chromosomal aberrations were scored.
2.3. Molecular analysis of FANCC gene mutations
Genomic DNA was obtained from peripheral blood of
patients enrolled in the study using the Chelex method
according to the manufacturer’s instructions. FANCC gene
mutations were analyzed by polymerase chain reaction
(PCR) followed by restriction site assays.
Primer sequences for the 3 loci (IVS4+4A>T,
del322G, R548X) were the same as previously reported
in the literature (13). Two of these primers for mutations
IVS4+4A>T and del322G introduced artificial restriction
sites into PCR products using primer-directed restriction
site modification. PCR was carried out in reactions of 20
µL with 150 ng of genomic DNA, 5 pM of each primer,
1X Master Mix (Fermentas Inc., USA), and distilled water.
After an initial denaturation at 94 °C for 5 min, samples
were amplified for 35 cycles of denaturation at 94 °C for 1
min, annealing for 1 min (50 °C for IVS4+4A>T, 56 °C for
del322G, 60 °C for R548X), and extension at 72 °C for 1
min followed by a final extension for 10 min at 72 °C.
Restriction assays were performed by using ScaI,
Bsp1286I, and AvaI restriction enzymes (Thermo
Scientific Inc., USA) according to the manufacturer’s
instructions for studying the three mutations of FANCC,
i.e. IVS4+4A>T, del322G, and R548X, respectively. The
reaction was prepared in a volume of 10 µL containing 3.5
µL of PCR product, 5 U of each enzyme, 0.6 µL of buffer,
and 5.5 µL water. The mixture was incubated for 30 min
at 37 °C (3 h for ScaI) to let the enzyme digest the PCR
product completely. After incubation, the enzyme was
deactivated by heating the tubes at 70 °C for 30 min. The
PCR digest was electrophoresed on 3% agarose gel. Image
Lab software was used to analyze the gel bands of normal
(digested into 2 fragments) and mutant (undigested, single
band) PCR products. The investigated gene mutations, the
sizes of their PCR products, their restriction sites, and the
sizes of the normal and mutant fragments obtained after
digestion are shown in Table 1.
SPSS 20 (IBM Corp., USA) was used for statistical
analysis. Continuous variables such as age, height, weight,
duration of illness, and laboratory parameters were
expressed as mean ± SD, whereas categorical variables
such as sex, clinical features, and mutations were given in
the form of frequency and percentage.
3. Results
A total of 36 unrelated FA patients (17 males and 19
females), ranging in age from 5 to 20 years, were included
in the study. Mean height and weight of patients was
123.06 ± 17.73 cm and 29.33 ± 13.07 kg respectively,
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Table 1. Size of PCR products, their respective restriction enzymes, and fragments obtained after digestion.
Mutation

PCR product (bp)

Restriction
enzyme

Restriction site

Size of product (bp) after
digestion

IVS4+4A>T

131

ScaI

A

N = 108+23
M = 131

Del322G

151

Bsp1286I

A

N = 129+22
M = 151

R548X

364

AvaI

Nat

N = 231+133
M = 364

ScaI- Streptomyces caespitosus; Bsp1286I- Bacillus sphaericus; AvaI- Anabaena variabilis;
A- artificial; Nat- natural; N- normal; M- mutated.

whereas duration of illness was 37.89 ± 31.15 months.
Thirty patients presented with congenital abnormalities
such as short stature, microcephaly, microphthalmia,
thumb abnormalities, café au lait spots, and congenital
absence of one kidney (Table 2). All patients had normal
serum electrolytes.
A variable degree of pancytopenia was present in
all patients. Onset of hematological abnormalities was
defined as the time at which a decrease in hemoglobin,
white blood cells, or platelets occurred. Mean hemoglobin
of patients was found to be 8.24 ± 2.57 g/dL while white

blood cell and platelet counts were (2.91 ± 1.42) × 109/L
and (62.78 ± 33.98) × 109/L, respectively. Complete blood
counts were done on a Sysmex (XT-1800i). All the patients
had bone marrow hypoplasia.
After amplification, restriction site assays were
developed for all three known pathogenic mutations. The
digested products were analyzed on 3% agarose gel. RFLP
results of the three mutations (IVS4+4A>T, del322G, and
R548X) are shown in Figures 1a–1c.
IVS4+4A>T was the most prevalent mutation in our
patients. It was detected in 26 (72.2%) patients; 20 (55.6%)

Table 2. Clinical characteristics of patients (n = 36).
Variable

Frequency

Percentage (%)

Male

17

47.2

Female

19

52.8

Consanguinity

24

66.7

Short stature

27

75

Low weight

20

55.6

Pallor

33

88.9

Epistaxis

19

52.8

Bruises

25

69.4

Microcephaly

23

63.9

Hypoplastic

11

30.6

Bifid

3

8.3

Microphthalmia

23

63.9

Café au lait spots

11

30.6

Absent kidney

3

8.3

Elevated liver enzymes

3

8.3

Sex

Thumb abnormalities

393

AFTAB et al. / Turk J Med Sci

a
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Figure 1. a) RFLP results of IVS4+4A>T mutation. A 100-bp ladder is shown on the extreme left side. Samples 5–13 are shown. Bands
of samples 5–9 are of 131 bp and they are homozygous for the mutation. Bands of samples 10–12 are of 108 bp and are normal for this
mutation. Sample 13 shows 2 bands of 108 and 131 bp and it is heterozygous for this mutation. b) RFLP results of del322G mutation.
A 100-bp ladder is shown on the left side. Samples 1–3 are shown. The band of sample 1 is of 129 bp and it is normal for this mutation.
Bands of samples 2 and 3 are of 129 and 151 bp and are heterozygous for this mutation. c) RFLP results of R548X mutation. A 50-bp
ladder is shown on the extreme left side. Sample 20 is heterozygous for this mutation, showing 3 bands of 133, 231, and 364 bp. Samples
21–28 are normal for this mutation, showing 2 bands of 133 and 231 bp.

were heterozygous and 6 (16.7%) were homozygous.
There were no homozygotes for the other two mutations.
The patients who were heterozygous for del322G also
had concomitant IVS4+4A>T mutation and they were
compound heterozygotes. The other 2 patients who were
heterozygous for R548X mutation were also compound
heterozygotes. In addition to R548X mutation, they also
had IVS4+4A>T mutations; one patient was homozygous
for IVS4+4A>T and the other was heterozygous for it, as
shown in Table 3.
Previous studies showed that patients homozygous for
IVS4+4A>T have a severe phenotype (14). We divided the
patients into two groups: homozygous for IVS4+4A>T
(group 1) and other patients including those heterozygous
for IVS4+4A>T and the rest of the patients (group 2). The
patients were compared on the basis of hematological
abnormalities and congenital malformations. There was no
significant difference in the clinical presentation of patients
of the 2 groups. Café au lait spots, congenital absence
of one kidney, and elevated liver enzymes were present
only in group 2 and microphthalmia and microcephaly
were slightly higher in group 1 but the difference was not
significant (Figure 2).
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4. Discussion
We have screened these three mutations of the FANCC
gene in 36 unrelated FA patients after confirming their
diagnosis by chromosomal breakage test. The mean age
of the studied group was 11.54 ± 4.26 years. Congenital
abnormalities were frequent and were equally distributed
in all patients. Most of the patients presented with severe
hematological manifestations including bone marrow
hypoplasia.
Previous studies showed that the distribution of FA
gene mutations is quite variable in different populations.
FANCC gene mutations are more common in Ashkenazi
Jews and the Japanese population (15,16). In the current
study, 72.2% of the patients (n = 26) were found to
have FANCC gene mutations, both homozygous and
heterozygous. Similarly, in another study conducted in
Brazil, FANCC gene mutations were found in two-thirds
of the patients (17).
IVS4+4A>T was the most common mutation found
in this study; 16.7% patients (n = 6) were homozygous
whereas the remaining 55.6% or 20 patients were
heterozygous (carriers) for this mutation. It was observed
that most of the patients (61.5%) recruited in this study
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Table 3. Molecular features of 36 patients with Fanconi anemia.
Case

Age (years) Sex

Abnormal gene

1

8

F

2

8

3

Genotype
IVS4+4A>T

R548X

Del322G

FANCC

IVS4+4A>T/ ̶

̶/̶

̶/̶

F

FANCC

IVS4+4A>T/ ̶

̶/̶

Del322G/ ̶

6

M

FANCC

IVS4+4A>T/ ̶

̶/̶

Del322G/ ̶

4

15

M

FANCC

IVS4+4A>T/ ̶

̶/̶

̶/̶

5

11

F

FANCC

IVS4+4A>T/IVS4+4A>T

̶/̶

̶/̶

6

6.5

M

FANCC

IVS4+4A>T/IVS4+4A>T

̶/̶

̶/̶

7

20

F

FANCC

IVS4+4A>T/IVS4+4A>T

̶/̶

̶/̶

8

15

M

FANCC

IVS4+4A>T/IVS4+4A>T

̶/̶

̶/̶

9

10

M

FANCC

IVS4+4A>T/IVS4+4A>T

̶/̶

̶/̶

10

17

F

NA

̶/̶

̶/̶

̶/̶

11

9

M

NA

̶/̶

̶/̶

̶/̶

12

8

F

NA

̶/̶

̶/̶

̶/̶

13

11

M

FANCC

IVS4+4A>T/ ̶

̶/̶

̶/̶

14

10

M

FANCC

IVS4+4A>T/IVS4+4A>T

R548X/ ̶

̶/̶

15

6

M

FANCC

IVS4+4A>T/ ̶

̶/̶

̶/̶

16

8

M

NA

̶/̶

̶/̶

̶/̶

17

12

F

NA

̶/̶

̶/̶

̶/̶

18

20

M

NA

̶/̶

̶/̶

̶/̶

19

18

F

FANCC

IVS4+4A>T/ ̶

̶/̶

̶/̶

20

14

M

FANCC

IVS4+4A>T/ ̶

R548X/ ̶

̶/̶

21

12

F

FANCC

IVS4+4A>T/ ̶

̶/̶

̶/̶

22

13

M

FANCC

IVS4+4A>T/ ̶

̶/̶

̶/̶

23

17

M

FANCC

IVS4+4A>T/ ̶

̶/̶

̶/̶

24

19

F

FANCC

IVS4+4A>T/ ̶

̶/̶

̶/̶

25

18

F

FANCC

IVS4+4A>T/ ̶

̶/̶

̶/̶

26

9

F

FANCC

IVS4+4A>T/ ̶

̶/̶

̶/̶

27

7

M

FANCC

IVS4+4A>T/ ̶

̶/̶

̶/̶

28

13

M

FANCC

IVS4+4A>T/ ̶

̶/̶

̶/̶

29

11

F

NA

̶/̶

̶/̶

̶/̶

30

10

F

FANCC

IVS4+4A>T/ ̶

̶/̶

̶/̶

31

5

F

FANCC

IVS4+4A>T/ ̶

̶/̶

̶/̶

32

7

F

FANCC

IVS4+4A>T/ ̶

̶/̶

̶/̶

33

8

F

FANCC

IVS4+4A>T/ ̶

̶/̶

̶/̶

34

10

M

NA

̶/̶

̶/̶

̶/̶

35

11

F

NA

̶/̶

̶/̶

̶/̶

36

13

F

NA

̶/̶

̶/̶

̶/̶

M- Male; F- female; NA- not available; (–/–): absence of both alleles.
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Figure 2. Comparison between groups 1 and 2.

were born of consanguineous marriages. Earlier it was
claimed by Verlander et al. that IVS4+4A>T is the most
common mutation in Ashkenazi Jews and is present in >80%
of FA patients (14). Later, an analysis of Ashkenazi Jews in
another study confirmed that this mutation is responsible
for most of the cases of FA among them and its carrier
frequency is 1 in 89. It was also suggested that this mutation
is extremely rare in other populations, as it was absent in
Iraqi Jews. The same results were confirmed by the IFAR
(18). In another study, it was reported that IVS4+4A>T was
the most prevalent mutation of the FANCC gene and it was
detected in 15.9% of Brazilian FA patients (17). The same
mutation was also present in 31% of Japanese patients. Of
these, 27.6% were homozygous. Moreover, these results
indicate that IVS4+4A>T mutation is also common in other
populations of non-Jewish origin (16).
FA is characterized by a wide variety of clinical
phenotypes. It has also been reported that in Ashkenazi
Jews, IVS4+4A>T is associated with a severe clinical
phenotype, multiple congenital abnormalities, and short
survival time in comparison with other FANCC gene
mutations or non-FANCC gene mutations (15). Contrary
to this, our patients with IVS4+4A>T mutation did not
exhibit phenotypic severity of that degree. However,
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Futaki et al. studied the same mutation and compared
homozygous patients with IVS4+4A>T mutation with the
rest of the patients. They concluded that it is not associated
with a severe phenotype in Japanese patients as it is seen
to be in Ashkenazi Jews (16). Therefore, to check the
association of IVS4+4A>T mutation with the severity of
disease in our population, patients were divided into 2
groups; group 1 included patients who were homozygous
for the mutation and group 2 included heterozygous cases
and the rest of the patients. Both groups were compared
on the basis of congenital and hematological abnormalities
and it was observed that there was no significant difference
in clinical presentations of disease between the 2 groups.
Congenital absence of one kidney, café au lait spots, and
elevated liver enzymes were absent in group 1 and were
present in group 2. We could not compare the survival
time of patients due to the limited time duration of the
study. Taken together, these results suggest that the
severity of the clinical phenotype is similar between
IVS4+4A>T homozygotes and other FA patients included
in our study. Wolf presented the same explanation in
his study: the same mutations can result in nonuniform
clinical pictures. He reported that phenotypic variations
do exist for the same mutations among different ethnic
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groups. It was stated that the presence of modifier genes
at other loci, epigenetic changes such as methylation, and
environmental influences such as exposure to pathogens
could be possible explanations. These factors might alter
the expression of mutations (19).
Screening of mutations, i.e. del322G and R548X, in
our patients revealed that each of these was present in
only 5.6% or 2 patients. All the patients were compound
heterozygotes. In the Brazilian population, del322G and
R548X were found to be 11.45% and 2.3%, respectively.
Compound heterozygosity with one mutated allele of both
IVS4+4A>T and del322G was also been described in the
same population (17). Gillio et al. found that compound
heterozygotes might have mild phenotypes (15), but we
did not observe any significant difference in the clinical
presentation between compound heterozygotes and other
patients.
In conclusion, we found that IVS4+4A>T mutation
was the only mutation present in a high frequency in
our patients and there was no significant difference in
the clinical presentation of homozygous cases and the
rest of the patients. The high frequency of IVS4+4A>T
homozygotes and compound heterozygotes was expected
as most of the patients were children of consanguineous

parents. Furthermore, heterozygous FA gene mutations
may also contribute to the severity and prognosis of the
disease because some of the mutations, as described
earlier, might have deleterious or protective effects
on other mutations. This indicates the importance of
molecular analysis for a better understanding of disease
pathology and diagnosis. Some concomitant mutations
have protective or deleterious effects on phenotype of
patients so it is recommended to analyze all the mutations
of the FANCC gene and correlate their effects with clinical
presentations of the patients and their parents to determine
their exact genotype for advanced FA research and gene
therapy.
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